Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6253097 | 0.89 | DHFR (0.42) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL2317607 | 0.83 | KDM4C (0.48) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL3451372 | 0.82 | HSD11B1 (0.43) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL15654560 | 0.82 | MEN1 (0.47) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL1755976 | 0.80 | HSD11B1 (0.41) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL20004827 | 0.80 | HSD11B1 (0.41) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL5535487 | 0.79 | HSD11B1 (0.40) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL2017636 | 0.79 | HSD11B1 (0.40) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL566012 | 0.78 | HSD11B1 (0.39) | DHFRHSD11B1KMT2AMEN1NPC1 | |
| SCHEMBL5702480 | 0.77 | DDB1 (0.41) | DHFRHSD11B1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | DHFR 4416/4885HSD11B1 555/4885KMT2A 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.